Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment.

Ganoderma lucidum

OncologyImmune supportMetabolic healthLiver support

SpeciesReishi, Lingzhi

JournalFrontiers in bioengineering and biotechnology

Year2022

Metadata-grounded summary

Article summary

Metadata-grounded summary: This journal article indexes research on Ganoderma lucidum in Frontiers in bioengineering and biotechnology in 2022. MycoData maps the paper to oncology, immune support, metabolic health, liver support based on its title, species context, article metadata, and study classification.

Citation

Abdullah NR, Mohd Nasir MH, Azizan NH, Wan-Mohtar WAAQI, Sharif F (2022). Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment. Frontiers in bioengineering and biotechnology https://doi.org/10.3389/fbioe.2022.960320 PMID: 36091430

Open citation